Skip to main content
OpenTrials
Completed

NCT Number: NCT02506257

Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects

Randomized, double-masked, placebo-controlled, multiple center, parallel-group Phase 1 study to evaluate the safety and tolerability of 3 doses of preservative-free PHMB ophthalmic solution compared to placebo in healthy subjects

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

About this study

The primary objective of the study is to establish the ocular safety and tolerability, and systemic safety of 3 different concentrations of preservative-free PHMB in healthy subjects. Safety and tolerability will be compared to those of a placebo.The PHMB bioavailability in plasma will also be assessed

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • able and willing to give informed consent.
  • man or woman of any race and 18 to 55 years of age, inclusive.
  • Body Mass Index of 20-30 kg/m2
  • willing and able to attend required study visits.
  • bilateral visual acuity >6/10.
  • intraocular pressure (IOP) of 14-21 mmHg.
  • ophthalmologic examination without abnormalities.
  • medical history without major pathology.
  • laboratory test results without deviations from the normal range.
  • female subjects of childbearing potential with negative urine pregnancy test and using effective contraception during the study.

Exclusion criteria

  • presence of bacterial ocular infections.
  • presence of any concomitant ocular pathology.
  • performing activities likely to result in an irritated conjunctiva during the study (including heavy alcohol intake, swimming in chlorinated water and heavy smoking).
  • contact lenses wearing .
  • ocular surface fluorescein staining score >3.
  • use of topical or systemic antibiotics, antihistamines, decongestants and non-steroidal anti-inflammatory agents as well as steroids within 7 days before screening.
  • known or suspected allergy to biguanides or intolerance to any other ingredient of the test treatments.
  • ocular surgery performed within 12 months before screening.
  • participation in another clinical study in the preceding 30 days.
  • one functional eye.
  • pregnancy or breastfeeding.
  • use of recreational drugs.

Treatment and study plan

0.04% PHMB

Drug

0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days

Other names: Polyhexamethylene Biguanide

0.06% PHMB

Drug

0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days

Other names: Polyhexamethylene Biguanide

0.08% PHMB

Drug

0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days

Other names: Polyhexamethylene Biguanide

PHMB Vehicle

Drug

PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days

Primary outcomes

  1. Number of Subjects With Dose-limiting Adverse Events

    Time frame: up to 21 days from date of randomization

Secondary outcomes

  1. Plasma Concentration of PHMB

    Time frame: Day14

Other outcomes

  1. Systolic Blood Pressure

    Time frame: Baseline and Day 14

    Change from baseline systolic blood pressure

  2. Visual Acuity

    Time frame: Baseline and Day 14

    Change from baseline Visual acuity. Best corrected visual acuity was reported in decimal fraction. A decrease of visual acuity during treatment was considered a negative safety outcome.

  3. Ocular Surface Disease Index-OSDI

    Time frame: Baseline and Day 14

    Change from baseline OSDI at D 14. Score range was betwwen 0-100. An increase of OSDI values with treatment represent a negative outcome.

  4. Conjunctival Examination

    Time frame: Baseline and Day 14

    Change from baseline conjunctival staining at Day 14. Staining with lissamine green was used. The density of staining was graded with the Oxford Score. Score range was between 0-15. An increase in the score after treatment represent a negative outcome

Sponsors and collaborators

Lead sponsor

SIFI SpA

Industry

Registry information

Official study title

Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Jul 23, 2015
Registry last updated
Feb 9, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.